\begin{landscape}
\begin{table}[H]
\centering
\tabcolsep=3pt
\renewcommand{\arraystretch}{1.3}
\tiny
\begin{threeparttable} 

\caption{\scriptsize{\textbf{Summary of published computational models for dapagliflozin.} 
Overview of published computational models including model type, software/platform, 
reproducibility criteria (open software, open model, open code, open data, 
reproducibility, FAIR, longterm storage), resources, clinical data sources, and model scope.}}
\label{tab:computational_models_overview}

\begin{tabularx}{\linewidth}{
    >{\raggedright\arraybackslash}p{1.6cm}  % Study
    >{\centering\arraybackslash}p{0.8cm}    % PubMed ID
    >{\raggedright\arraybackslash}p{1.0cm}  % Model Type
    >{\raggedright\arraybackslash}p{1.6cm}  % Platform/Software
    >{\centering\arraybackslash}p{0.8cm}    % Open Software
    >{\centering\arraybackslash}p{0.8cm}    % Open Model
    >{\centering\arraybackslash}p{0.8cm}    % Open Code
    >{\centering\arraybackslash}p{0.8cm}    % Open Data
    >{\centering\arraybackslash}p{0.8cm}    % Reproducibility
    >{\centering\arraybackslash}p{0.8cm}    % FAIR
    >{\centering\arraybackslash}p{0.8cm}    % Longterm Storage
    >{\centering\arraybackslash}p{2.3cm}    % Resources
    >{\centering\arraybackslash}p{0.7cm}    % Studies
    >{\raggedright\arraybackslash}p{3.0cm}  % Clinical Data Used
    >{\raggedright\arraybackslash}p{5.0cm}  % Scope
}
\toprule
\textbf{Study} & \textbf{PubMed ID} & \textbf{Model Type} & \textbf{Platform/Software} & \textbf{Open Software} & \textbf{Open Model} & \textbf{Open Code} & \textbf{Open Data} & \textbf{Reproducibility} & \textbf{FAIR} & \textbf{Longterm Storage} & \textbf{Resources} & \textbf{Studies} & \textbf{Clinical Data Used} & \textbf{Scope} \\
\midrule
Balazki2018 \cite{Balazki2018} & \href{https://pubmed.ncbi.nlm.nih.gov/30270578/}{30270578} & QSP + PBPK/PD & PK-Sim, MoBi, OSPS, R & \cellcolor{green!20}Yes & \cellcolor{green!20}Yes & \cellcolor{green!20}Yes & \cellcolor{green!20}Yes & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & https://github.com/Open-Systems-Pharmacology/SGLT2i-hyperfiltration-model Model, Data, Code in supplement; & 7 & 7 clinical studies; digitized literature data & Renal hyperfiltration, tubuloglomerular feedback, glucose-sodium reabsorption, SGLT2 inhibition effects on GFR \\
\addlinespace[1pt]
Busse2019 \cite{Busse2019} & \href{https://pubmed.ncbi.nlm.nih.gov/31077437/}{31077437} & PopPK + PK/PD & NONMEM, PsN, R & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & - & 2 & 2 clinical studies (T1DM adolescents + adults; PK + UGE ER); clinical studies referenced & Pharmacokinetics, exposure-urinary glucose excretion relationship, body weight and eGFR effects in Type 1 diabetes (adolescents vs adults) \\
\addlinespace[1pt]
Callegari2021 \cite{Callegari2021} & \href{https://pubmed.ncbi.nlm.nih.gov/33314761/}{33314761} & PBPK & Simcyp & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & - & 1 & 1 clinical DDI study (ertugliflozin + mefenamic acid), literature PK for dapagliflozin; & PBPK modeling (ertugliflozin), UGT-mediated drug-drug interaction prediction with mefenamic acid, absorption and metabolism pathways \\
\addlinespace[1pt]
Guo2025 \cite{Guo2025} & \href{https://pubmed.ncbi.nlm.nih.gov/40230691/}{40230691} & PBPK/PD & PK-Sim, MoBi, OriginLab & \cellcolor{green!20}Yes & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & - & 25 & ~25 clinical PK/PD studies & PBPK/PD modeling of four SGLT2 inhibitors (dapagliflozin, canagliflozin, empagliflozin, ipragliflozin), enal tubule structure, renal glucose reabsorption, urinary glucose excretion, dose optimization in T2DM with renal insufficiency \\
\addlinespace[1pt]
Jo2021 \cite{Jo2021} & \href{https://pubmed.ncbi.nlm.nih.gov/33439535/}{33439535} & PBPK & Simcyp & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & - & 7 & 7 clinical studies; trials registered on ClinicalTrials.gov & PBPK model incorporating UGT1A9 ontogeny for pediatric dose selection, DDIs with rifampin/mefenamic acid, hepatic/renal impairment predictions \\
\addlinespace[1pt]
Maurer2011 \cite{Maurer2011} & \href{https://pubmed.ncbi.nlm.nih.gov/21870203/}{21870203} & PK/PD & NONMEM & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & - & 1 & 1 published study: Komoroski et al. 2009; digitized literature data; data not shared & Biologically-based PK/PD model of UGE, rat-to-human translational pharmacology \\
\addlinespace[1pt]
Mori2016 \cite{Mori2016} & \href{https://pubmed.ncbi.nlm.nih.gov/27604638/}{27604638} & PBPK/PD & Simcyp, simBio & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & - & 14 & 14 studies total: 8 canagliflozin studies, 6 dapagliflozin studies; clinical studies referenced & PBPK/PD model predicting canagliflozin and dapagliflozin concentrations in intestinal lumen and renal proximal tubules, SGLT1/2 inhibition ratios, urinary glucose excretion validation \\
\addlinespace[1pt]
Shah2021 \cite{Shah2021} & \href{https://pubmed.ncbi.nlm.nih.gov/33368935/}{33368935} & QSP PK/PD & Monolix, R & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & - & 5 & 5 studies total (1 phase IIa + 4 phase III), trials registered on ClinicalTrials.gov & Quantitative systems pharmacology (QSP) model integrating dapagliflozin PK, glucose-insulin homeostasis, renal glucose reabsorption, and HbA1c formation to predict treatment effect in T2DM patients \\
\addlinespace[1pt]
Shahidehpour2024 \cite{Shahidehpour2024} & \href{https://pubmed.ncbi.nlm.nih.gov/39160349/}{39160349} & Mechanistic PK & Python & \cellcolor{green!20}Yes & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & - & - & Secondary literature values (number of studies not specified) & Methodology for estimating drug clearance in chronic kidney disease (CKD) using probability density functions from secondary data, mechanistic models, and PK first principles—applied to metformin and dapagliflozin PK modeling and dose adjustment \\
\addlinespace[1pt]
Sokolov2019 \cite{Sokolov2019} & \href{https://pubmed.ncbi.nlm.nih.gov/30456904/}{30456904} & PK/PD & NONMEM, R & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & - & 2 & 2 clinical studies (not publicly available) & Exposure-response modeling of dapagliflozin PK and 24h-UGE in T1DM patients, comparing Japanese vs non-Japanese populations with covariate effects (eGFR, SMBG, insulin dose) \\
\addlinespace[1pt]
vanderAart\-vanderBeek2021 \cite{vanderAartvanderBeek2021} & \href{https://pubmed.ncbi.nlm.nih.gov/33587286/}{33587286} & PopPK & NONMEM, R & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & - & 1 & 1 clinical trial & Population PK modeling in non-diabetic CKD patients and linking exposure to changes in kidney risk markers \\
\addlinespace[1pt]
VanDerWalt2013 \cite{VanDerWalt2013} & \href{https://pubmed.ncbi.nlm.nih.gov/23887724/}{23887724} & PopPK & NONMEM, R & \cellcolor{red!20}No & \cellcolor{green!20}Yes & \cellcolor{green!20}Yes & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & NONMEM code in supplement & 3 & 3 clinical studies & Population PK model for dapagliflozin and its inactive metabolite D3OG, quantifying renal vs hepatic contributions to UGT1A9-mediated metabolism in subjects with renal/hepatic impairment \\
\addlinespace[1pt]
Yao2023 \cite{Yao2023} & \href{https://pubmed.ncbi.nlm.nih.gov/36890732/}{36890732} & Meta-analytic PK/PD & NONMEM, R & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & \cellcolor{red!20}No & - & 80 & 80 papers across 3 drugs; digitized literature data; data not shared & Study-level meta-analysis of PK/PD relationships across SGLT2 inhibitors \\
\addlinespace[1pt]
Nemitz2025 \cite{Nemitz2025} & - & PBPK/PD & SBML, Python & \cellcolor{green!20}Yes & \cellcolor{green!20}Yes & \cellcolor{green!20}Yes & \cellcolor{green!20}Yes & \cellcolor{green!20}Yes & \cellcolor{green!20}Yes & \cellcolor{green!20}Yes & https://github.com/matthiaskoenig/dapagliflozin-model Model, Data, Code in github repository; CI/CD workflow for reproducibility; longterm storage on zenodo: https://doi.org/10.5281/zenodo.13987865  & 28 & 28 clinical studies; digitized literature data & Whole-body mechanistic PBPK/PD model of dapagliflozin linking ADME to SGLT2-mediated urinary glucose excretion and renal threshold for glucose, capturing dose dependency, renal and hepatic impairment, and food effects, implemented in SBML with full FAIR compliance \\
\addlinespace[1pt]
\bottomrule
\end{tabularx}

\end{threeparttable} 
\end{table}
\end{landscape}